ABBV Collar Strategy
ABBV (AbbVie Inc.), in the Healthcare sector, (Drug Manufacturers - General industry), listed on NYSE.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV (AbbVie Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - General, with a market capitalization of approximately $368.38B, a trailing P/E of 101.64, a beta of 0.31 versus the broader market, a 52-week range of 176.57-244.81, average daily share volume of 6.9M, a public-listing history dating back to 2013, approximately 55K full-time employees. These structural characteristics shape how ABBV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.31 indicates ABBV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 101.64 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple. ABBV pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a collar on ABBV?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current ABBV snapshot
As of May 15, 2026, spot at $210.80, ATM IV 25.84%, IV rank 43.94%, expected move 7.41%. The collar on ABBV below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this collar structure on ABBV specifically: IV regime affects collar pricing on both sides; mid-range ABBV IV at 25.84% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 7.41% (roughly $15.61 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABBV expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABBV should anchor to the underlying notional of $210.80 per share and to the trader's directional view on ABBV stock.
ABBV collar setup
The ABBV collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABBV near $210.80, the first option leg uses a $220.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABBV chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABBV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $210.80 | long |
| Sell 1 | Call | $220.00 | $2.54 |
| Buy 1 | Put | $200.00 | $2.11 |
ABBV collar risk and reward
- Net Premium / Debit
- -$21,037.50
- Max Profit (per contract)
- $962.50
- Max Loss (per contract)
- -$1,037.50
- Breakeven(s)
- $210.38
- Risk / Reward Ratio
- 0.928
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
ABBV collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on ABBV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$1,037.50 |
| $46.62 | -77.9% | -$1,037.50 |
| $93.23 | -55.8% | -$1,037.50 |
| $139.83 | -33.7% | -$1,037.50 |
| $186.44 | -11.6% | -$1,037.50 |
| $233.05 | +10.6% | +$962.50 |
| $279.66 | +32.7% | +$962.50 |
| $326.27 | +54.8% | +$962.50 |
| $372.87 | +76.9% | +$962.50 |
| $419.48 | +99.0% | +$962.50 |
When traders use collar on ABBV
Collars on ABBV hedge an existing long ABBV stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
ABBV thesis for this collar
The market-implied 1-standard-deviation range for ABBV extends from approximately $195.19 on the downside to $226.41 on the upside. A ABBV collar hedges an existing long ABBV position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current ABBV IV rank near 43.94% is mid-range against its 1-year distribution, so the IV signal is neutral; the collar thesis on ABBV should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABBV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABBV-specific events.
ABBV collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABBV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABBV alongside the broader basket even when ABBV-specific fundamentals are unchanged. Always rebuild the position from current ABBV chain quotes before placing a trade.
Frequently asked questions
- What is a collar on ABBV?
- A collar on ABBV is the collar strategy applied to ABBV (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With ABBV stock trading near $210.80, the strikes shown on this page are snapped to the nearest listed ABBV chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABBV collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the ABBV collar priced from the end-of-day chain at a 30-day expiry (ATM IV 25.84%), the computed maximum profit is $962.50 per contract and the computed maximum loss is -$1,037.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABBV collar?
- The breakeven for the ABBV collar priced on this page is roughly $210.38 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABBV market-implied 1-standard-deviation expected move is approximately 7.41%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on ABBV?
- Collars on ABBV hedge an existing long ABBV stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current ABBV implied volatility affect this collar?
- ABBV ATM IV is at 25.84% with IV rank near 43.94%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.